Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 14/20 | 0.50 |
| ▸ | OGA | O60502 | 2/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24118615 | 0.83 | IDO1 (0.68) | IDO1TRPM8 | |
| SCHEMBL21496467 | 0.83 | IDO1 (0.68) | IDO1TRPM8 | |
| SCHEMBL21496468 | 0.83 | IDO1 (0.68) | IDO1TRPM8 | |
| SCHEMBL21504297 | 0.80 | IDO1 (0.52) | IDO1SMN1; SMN2 | |
| SCHEMBL23572579 | 0.74 | IDO1 (0.60) | IDO1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL29639853 | 0.74 | IDO1 (0.60) | IDO1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL21496393 | 0.72 | IDO1 (0.63) | IDO1 | |
| SCHEMBL30055593 | 0.72 | IDO1 (0.63) | IDO1 | |
| SCHEMBL24118309 | 0.71 | IDO1 (0.74) | IDO1MAPTSMN1; SMN2 | |
| SCHEMBL30055468 | 0.71 | IDO1 (0.74) | IDO1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210393600-A1 | Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393600-A1 | Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors | IDO1, IDO2, TPH1 | IDO1 1/4885OGA 1128/4885TRPM8 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.